{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:22:09Z","timestamp":1785295329511,"version":"3.55.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["33IC30_166785\/1"],"award-info":[{"award-number":["33IC30_166785\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCCR TransCure"},{"name":"NCCR Kidney"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Autosomal dominant polycystic kidney disease (ADPKD) is characterized by a unique bone and mineral phenotype. The impact of tolvaptan treatment on mineral metabolism and bone mineral density (BMD) is unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted an analysis in the Bern ADPKD Registry, a prospective observational cohort study. Mineral metabolism parameters were measured at baseline and every 12\u00a0months thereafter. BMD was determined by dual-energy X-ray absorptiometry at baseline and after 3\u00a0years. Multivariable mixed-effects regression models were applied to assess changes in mineral metabolism parameters and BMD associated with tolvaptan treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 189 participants (122 without and 67 with subsequent tolvaptan treatment) were included in the analysis. During follow-up, tolvaptan treatment was associated with increased BMD at the femoral neck {\u03b2\u00a0=\u00a00.092 [95% confidence interval (CI) 0.001\u20130.183], P\u00a0=\u00a0.047}. In addition, tolvaptan treatment was associated with higher plasma magnesium [\u03b2\u00a0=\u00a00.019 (95% CI 0.001\u20130.037), P\u00a0=\u00a0.037], bicarbonate [\u03b2\u00a0=\u00a00.972 (95% CI 0.242\u20131.702), P\u00a0=\u00a0.009] and urine pH [\u03b2\u00a0=\u00a00.214 (95% CI 0.056\u20130.372), P\u00a0=\u00a0.008] and lower parathyroid hormone [\u03b2\u00a0=\u00a0\u22120.191 (95% CI \u22120.328 to \u22120.053), P\u00a0=\u00a0.006], 1,25(OH)D3 [\u03b2\u00a0=\u00a0\u22120.126 (95% CI \u22120.235 to \u22120.164), P\u00a0=\u00a0.024] and fractional urinary magnesium excretion [\u03b2\u00a0=\u00a0\u22120.473 (95% CI \u22120.622 to \u22120.324), P\u00a0&amp;lt;\u00a0.001].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Chronic tolvaptan treatment is associated with increased femoral BMD and significant changes in both mineral metabolism and acid\u2013base parameters in ADPKD patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfac298","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T02:40:41Z","timestamp":1667097641000},"page":"1645-1654","source":"Crossref","is-referenced-by-count":5,"title":["Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients"],"prefix":"10.1093","volume":"38","author":[{"given":"Matteo","family":"Bargagli","sequence":"first","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland"},{"name":"Universit\u00e0 Cattolica del Sacro Cuore , Rome , Italy"},{"name":"U.O.C. Nefrologia, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andri","family":"Vetsch","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel A","family":"Anderegg","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser A","family":"Dhayat","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uyen","family":"Huynh-Do","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Faller","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Vogt","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro Manuel","family":"Ferraro","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Cattolica del Sacro Cuore , Rome , Italy"},{"name":"U.O.C. Nefrologia, Fondazione Policlinico Universitario A. Gemelli IRCCS , Rome , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G","family":"Fuster","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern , Bern , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"2023063001055900500_bib1","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.3390\/ijms20092182","article-title":"Polycystins and mechanotransduction in human disease","volume":"20","author":"Gargalionis","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2023063001055900500_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ki.2015.59","article-title":"Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"88","author":"Chapman","year":"2015","journal-title":"Kidney Int"},{"key":"2023063001055900500_bib3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/ndt\/gft437","article-title":"Extra-renal manifestations of autosomal dominant polycystic kidney disease (ADPKD): considerations for routine screening and management","volume":"29","author":"Luciano","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2023063001055900500_bib4","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1096\/fj.10-180299","article-title":"Conditional deletion of Pkd1 in osteocytes disrupts skeletal mechanosensing in mice","volume":"25","author":"Xiao","year":"2011","journal-title":"FASEB J"},{"key":"2023063001055900500_bib5","doi-asserted-by":"crossref","first-page":"30884","DOI":"10.1074\/jbc.M604772200","article-title":"Cilia-like structures and polycystin-1 in osteoblasts\/osteocytes and associated abnormalities in skeletogenesis and Runx2 expression","volume":"281","author":"Xiao","year":"2006","journal-title":"J Biol Chem"},{"key":"2023063001055900500_bib6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.kint.2020.07.041","article-title":"Mineral bone disease in autosomal dominant polycystic kidney disease","volume":"99","author":"Gitomer","year":"2021","journal-title":"Kidney Int"},{"key":"2023063001055900500_bib7","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1210\/jc.2017-01157","article-title":"Evidence for bone and mineral metabolism alterations in children with autosomal dominant polycystic kidney disease","volume":"102","author":"De Rechter","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2023063001055900500_bib8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2215\/CJN.09020911","article-title":"Soluble klotho and autosomal dominant polycystic kidney disease","volume":"7","author":"Pavik","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023063001055900500_bib9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/ki.2010.375","article-title":"Patients with autosomal dominant polycystic kidney disease have elevated fibroblast growth factor 23 levels and a renal leak of phosphate","volume":"79","author":"Pavik","year":"2011","journal-title":"Kidney Int"},{"key":"2023063001055900500_bib10","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.kint.2018.09.018","article-title":"A distinct bone phenotype in ADPKD patients with end-stage renal disease","volume":"95","author":"Evenepoel","year":"2019","journal-title":"Kidney Int"},{"key":"2023063001055900500_bib11","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"2023063001055900500_bib12","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"2023063001055900500_bib13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2215\/CJN.13861119","article-title":"Urinary lithogenic risk profile in ADPKD patients treated with tolvaptan","volume":"15","author":"Bargagli","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023063001055900500_bib14","doi-asserted-by":"crossref","first-page":"18644","DOI":"10.1073\/pnas.1318257110","article-title":"Regulation of bone remodeling by vasopressin explains the bone loss in hyponatremia","volume":"110","author":"Tamma","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023063001055900500_bib15","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1210\/jc.2014-1572","article-title":"Recovery from SIADH-associated osteoporosis: a case report","volume":"99","author":"Sejling","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2023063001055900500_bib16","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1210\/jc.2012-2031","article-title":"Syndrome of inappropriate ADH secretion and severe osteoporosis","volume":"97","author":"Sejling","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2023063001055900500_bib17","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1210\/jc.2015-1261","article-title":"Hyponatremia is associated with increased osteoporosis and bone fractures in a large US health system population","volume":"100","author":"Usala","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2023063001055900500_bib18","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s00198-014-2973-1","article-title":"Hyponatremia and osteoporosis: insights from the Danish National Patient Registry","volume":"26","author":"Kruse","year":"2015","journal-title":"Osteoporos Int"},{"key":"2023063001055900500_bib19","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1073\/pnas.1523762113","article-title":"Functions of vasopressin and oxytocin in bone mass regulation","volume":"113","author":"Sun","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"2023063001055900500_bib20","doi-asserted-by":"crossref","first-page":"10864","DOI":"10.1074\/jbc.M110.155002","article-title":"Osteoclast response to low extracellular sodium and the mechanism of hyponatremia-induced bone loss","volume":"286","author":"Barsony","year":"2011","journal-title":"J Biol Chem"},{"key":"2023063001055900500_bib21","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(94)92026-5","article-title":"Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1","volume":"343","author":"Ravine","year":"1994","journal-title":"Lancet"},{"key":"2023063001055900500_bib22","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1681\/ASN.2013101138","article-title":"Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials","volume":"26","author":"Irazabal","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2023063001055900500_bib23","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2023063001055900500_bib24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/ki.1989.280","article-title":"A new method for estimating G-I absorption of alkali","volume":"36","author":"Oh","year":"1989","journal-title":"Kidney Int"},{"key":"2023063001055900500_bib25","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00198-015-3440-3","article-title":"The National Osteoporosis Foundation's position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations","volume":"27","author":"Weaver","year":"2016","journal-title":"Osteoporos Int"},{"key":"2023063001055900500_bib26","doi-asserted-by":"crossref","first-page":"115475","DOI":"10.1016\/j.bone.2020.115475","article-title":"The impact of thiazide diuretics on bone mineral density and the trabecular bone score: the Rotterdam Study","volume":"138","author":"van der Burgh","year":"2020","journal-title":"Bone"},{"key":"2023063001055900500_bib27","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1210\/er.2012-1042","article-title":"The impact of diabetes and diabetes medications on bone health","volume":"36","author":"Gilbert","year":"2015","journal-title":"Endocr Rev"},{"key":"2023063001055900500_bib28","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1080\/07315724.2006.10719536","article-title":"Dietary acid-base balance, bone resorption, and calcium excretion","volume":"25","author":"Jajoo","year":"2006","journal-title":"J Am Coll Nutr"},{"key":"2023063001055900500_bib29","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1037\/a0020761","article-title":"A general approach to causal mediation analysis","volume":"15","author":"Imai","year":"2010","journal-title":"Psychol Methods"},{"key":"2023063001055900500_bib30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1210\/jcem.84.2.5498","article-title":"Parathyroid hormone deficiency and excess: similar effects on trabecular bone but differing effects on cortical bone","volume":"84","author":"Duan","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2023063001055900500_bib31","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ekir.2021.12.003","article-title":"Predictors of bone mineral density in kidney stone formers","volume":"7","author":"Dhayat","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2023063001055900500_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.2007.00001.x","article-title":"Tolvaptan, an orally active vasopressin V2-receptor antagonist\u2014pharmacology and clinical trials","volume":"25","author":"Miyazaki","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"issue":"Suppl 1","key":"2023063001055900500_bib33","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.2215\/CJN.05910809","article-title":"Calcium metabolism in health and disease","volume":"5","author":"Peacock","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023063001055900500_bib34","doi-asserted-by":"crossref","first-page":"h4183","DOI":"10.1136\/bmj.h4183","article-title":"Calcium intake and bone mineral density: systematic review and meta-analysis","volume":"351","author":"Tai","year":"2015","journal-title":"BMJ"},{"key":"2023063001055900500_bib35","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1681\/ASN.2018080816","article-title":"Vasopressin increases urinary acidification via V1a receptors in collecting duct intercalated cells","volume":"30","author":"Giesecke","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2023063001055900500_bib36","doi-asserted-by":"crossref","first-page":"F1166","DOI":"10.1152\/ajprenal.00196.2007","article-title":"Vasopressin V2 receptor expression along rat, mouse, and human renal epithelia with focus on TAL","volume":"293","author":"Mutig","year":"2007","journal-title":"Am J Physiol Renal Physiol"},{"key":"2023063001055900500_bib37","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1152\/physrev.2001.81.1.51","article-title":"Magnesium transport in the renal distal convoluted tubule","volume":"81","author":"Dai","year":"2001","journal-title":"Physiol Rev"},{"key":"2023063001055900500_bib38","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF02584009","article-title":"Effects of antidiuretic hormone, parathyroid hormone and glucagon on transepithelial voltage and resistance of the cortical and medullary thick ascending limb of Henle's loop of the mouse nephron","volume":"415","author":"Wittner","year":"1990","journal-title":"Pflugers Archiv"},{"key":"2023063001055900500_bib39","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1007\/BF00583948","article-title":"Stimulation of tubular reabsorption of magnesium and calcium by antidiuretic hormone in conscious rats: study in Brattleboro rats with hereditary hypothalamic diabetes insipidus","volume":"402","author":"Bouby","year":"1984","journal-title":"Pflugers Archiv"},{"key":"2023063001055900500_bib40","first-page":"F156","article-title":"Stimulation by antidiuretic hormone of electrolyte tubular reabsorption in rat kidney","volume":"244","author":"de Rouffignac","year":"1983","journal-title":"Am J Physiol"},{"key":"2023063001055900500_bib41","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1681\/ASN.2017080849","article-title":"Magnesium and risk of hip fracture among patients undergoing hemodialysis","volume":"29","author":"Sakaguchi","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2023063001055900500_bib42","doi-asserted-by":"crossref","first-page":"F830","DOI":"10.1152\/ajprenal.00587.2010","article-title":"Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone","volume":"300","author":"Wesson","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"key":"2023063001055900500_bib43","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1172\/JCI105467","article-title":"The effects of chronic acid loads in normal man: further evidence for the participation of bone mineral in the defense against chronic metabolic acidosis","volume":"45","author":"Lemann","year":"1966","journal-title":"J Clin Invest"},{"key":"2023063001055900500_bib44","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s10157-013-0783-y","article-title":"The intercalated cells of the mouse kidney OMCDis are the target of the vasopressin V1a receptor axis for urinary acidification","volume":"17","author":"Yasuoka","year":"2013","journal-title":"Clin Exp Nephrol"},{"key":"2023063001055900500_bib45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.kisu.2017.04.001","article-title":"KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD)","volume":"7","year":"2017","journal-title":"Kidney Int Suppl"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfac298\/47195025\/gfac298.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/7\/1645\/50701809\/gfac298.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/38\/7\/1645\/50701809\/gfac298.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T01:06:32Z","timestamp":1688087192000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/38\/7\/1645\/6780211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,10,29]]},"published-print":{"date-parts":[[2023,6,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfac298","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7]]},"published":{"date-parts":[[2022,10,29]]}}}